ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Impact of Extended- versus Immediate-Release Tacrolimus on One-Year Development of De Novo DSA and Chronic Immune Activation in Kidney Transplantation (ASTOUND Study)

A. Wiseman1, D. Kaufman2, A. Patel3, D. Wojciechowski4, A. Tambur5, J. Kim6, J. Schwartz6

1University of Colorado Hospital, Aurora, CO, 2University of Wisconsin, Madison, WI, 3Henry Ford Hospital, Detroit, MS, 4Massachusetts General Hospital, Boston, MA, 5Northwestern University, Chicago, IL, 6Astellas Pharma Global Development, Northbrook, IL

Meeting: 2020 American Transplant Congress

Abstract number: LB-5

Keywords: Immunosuppression, Kidney transplantation, Multicenter studies

Session Information

Session Name: Late Breaking Oral Abstract

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:03pm-4:15pm

Location: Virtual

*Purpose: To compare, using an adaptive study design, the 1-year incidence of a novel two-part composite endpoint consisting of de novo donor-specific antibody (dnDSA) formation and/or immune activation (IA) in kidney transplant (Ktx) recipients maintained on extended- (ERT) vs immediate-release tacrolimus (IRT).

*Methods: In this exploratory, prospective, multicenter, randomized, open-label trial (NCT02723591), 599 adult Ktx recipients were randomized 1:1 to receive once daily ERT (Astagraf XL®, Astellas Pharma US, Inc.) or twice daily IRT maintenance immunosuppression with corticosteroids and mycophenolate mofetil (target tacrolimus trough concentration ≥6 ng/mL). Positivity for dnDSA was defined as MFI >1000. IA was defined as a positive peripheral blood molecular signature as measured by the Trugraf™ v2.0 molecular assay (Transplant Genomics, Inc., USA). The difference in the proportion of patients meeting the primary composite endpoint was assessed by testing the null hypothesis of no treatment effect (H0: odds ratio [OR]=1; multivariable logistic regression analysis).

*Results: Safety was analyzed in 575 and efficacy in 554 patients (confirmed DSA negative at time of tx; ERT, n=275; IRT, n=279). By Day 365, incidence of the novel primary composite endpoint (dnDSA and/or IA) was 35.6% in the ERT group vs 34.4% in the IRT group (Table). Adjusted OR for ERT vs IRT was 1.12 (95% CI: 0.76, 1.64; p=0.58). Incidence of the traditional four-part composite endpoint of biopsy-proven acute rejection (BPAR), graft loss, death, or loss to follow-up was 9.1% vs 10.4%, respectively. Mean relative improvements in eGFR from Day 30 to Day 365 were 19.7% for ERT and 20.8% for IRT (respective mean increase, 6.04 vs 6.39 mL/min/1.73 m²). Mean eGFR at Day 365 was 58.25 vs 60.86 mL/min/1.73 m². BK virus was reported in 15.6% and 12.9% of patients, respectively. No unexpected safety findings were reported.

*Conclusions: This is the first large-scale RCT in the field of solid organ tx to use potential biomarkers as the primary outcome measure. At 1 year post tx, incidence rates of dnDSA formation and BPAR were similar with ERT and IRT. dnDSA rates were lower than historically reported. Both tacrolimus formulations yielded 1-year death-censored graft survival >98% under contemporary US practice conditions.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Wiseman A, Kaufman D, Patel A, Wojciechowski D, Tambur A, Kim J, Schwartz J. Impact of Extended- versus Immediate-Release Tacrolimus on One-Year Development of De Novo DSA and Chronic Immune Activation in Kidney Transplantation (ASTOUND Study) [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-extended-versus-immediate-release-tacrolimus-on-one-year-development-of-de-novo-dsa-and-chronic-immune-activation-in-kidney-transplantation-astound-study/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences